Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China

Cytovia Therapeutics Inc and Cellectis SA CLLS have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells.
The expanded agreement will include a new CAR target and development in China by Cytovia's joint venture entity, CytoLynx Therapeutics.
The amended financial terms include an equity stake of $20 million in Cytovia stock and up to $805 million in milestones and single-digit sales-based royalty payments.
Cytovia will develop iNK products leveraging Cellectis' TALEN to perform gene-editing to minimize the risk of off-target effects and unlock the full potential of NK cells as the first line of defense against cancer.
Cytovia is responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and is conducting the preclinical evaluation, clinical development, and commercialization.
Related Link: Cellectis Unveils Four Additional Preclinical Candidates For Solid Tumors.
Price Action: CLLS shares closed at $9.1 on Thursday.